{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T21:15:15Z","timestamp":1740172515460,"version":"3.37.3"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T00:00:00Z","timestamp":1655337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T00:00:00Z","timestamp":1655337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["ICMx"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Immune cell dysfunction plays a central role in sepsis-associated immune paralysis. The transfusion of healthy donor immune cells, i.e., granulocyte concentrates (GC) potentially induces tissue damage via local effects of neutrophils. Initial clinical trials using standard donor GC in a strictly extracorporeal bioreactor system for treatment of septic shock patients already provided evidence for beneficial effects with fewer side effects, by separating patient and donor immune cells using plasma filters. In this ex vivo study, we demonstrate the functional characteristics of a simplified extracorporeal therapy system using purified granulocyte preparations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Purified GC were used in an immune cell perfusion model prefilled with human donor plasma simulating a 6-h treatment. The extracorporeal circuit consisted of a blood circuit and a plasma circuit with 3 plasma filters (PF). PF1 is separating the plasma from the patient\u2019s blood. Plasma is then perfused through PF2 containing donor immune cells and used in a dead-end mode. The filtrated plasma is finally retransfused to the blood circuit. PF3 is included in the plasma backflow as a redundant safety measure. The donor immune cells are retained in the extracorporeal system and discarded after treatment. Phagocytosis activity, oxidative burst and cell viability as well as cytokine release and metabolic parameters of purified GCs were assessed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Cells were viable throughout the study period and exhibited well-preserved functionality and efficient metabolic activity. Course of lactate dehydrogenase and free hemoglobin concentration yielded no indication of cell impairment. The capability of the cells to secret various cytokines was preserved. Of particular interest is equivalence in performance of the cells on day 1 and day 3, demonstrating the sustained shelf life and performance of the immune cells in the purified GCs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Results demonstrate the suitability of a simplified extracorporeal system. Furthermore, granulocytes remain viable and highly active during a 6-h treatment even after storage for 3\u00a0days supporting the treatment of septic patients with this system in advanced clinical trials.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40635-022-00453-8","type":"journal-article","created":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T13:05:52Z","timestamp":1655384752000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Extracorporeal immune cell therapy of sepsis: ex vivo results"],"prefix":"10.1186","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8922-8700","authenticated-orcid":false,"given":"Gerd","family":"Klinkmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Wild","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Heskamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanny","family":"Doss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Doss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lubomir","family":"Arseniev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krasimira","family":"Aleksandrova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Sauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel A.","family":"Reuter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steffen","family":"Mitzner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Altrichter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,16]]},"reference":[{"key":"453_CR1","doi-asserted-by":"publisher","first-page":"e1063","DOI":"10.1097\/CCM.0000000000005337","volume":"49","author":"L Evans","year":"2021","unstructured":"Evans L, Rhodes A, Alhazzani W et al (2021) Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Crit Care Med 49:e1063. https:\/\/doi.org\/10.1097\/CCM.0000000000005337","journal-title":"Crit Care Med"},{"key":"453_CR2","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.3389\/fimmu.2018.01926","volume":"9","author":"AM Peters van Ton","year":"2018","unstructured":"Peters van Ton AM, Kox M, Abdo WF, Pickkers P (2018) Precision Immunotherapy for Sepsis. Front Immunol 9:1926. https:\/\/doi.org\/10.3389\/fimmu.2018.01926","journal-title":"Front Immunol"},{"key":"453_CR3","doi-asserted-by":"publisher","first-page":"R183","DOI":"10.1186\/cc10332","volume":"15","author":"GP Otto","year":"2011","unstructured":"Otto GP, Sossdorf M, Claus RA et al (2011) The late phase of sepsis is characterized by an increased microbiological burden and death rate. Crit Care 15:R183. https:\/\/doi.org\/10.1186\/cc10332","journal-title":"Crit Care"},{"key":"453_CR4","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1001\/jama.300.4.413","volume":"300","author":"AP Limaye","year":"2008","unstructured":"Limaye AP, Kirby KA, Rubenfeld GD et al (2008) Cytomegalovirus reactivation in critically ill immunocompetent patients. JAMA 300:413\u2013422. https:\/\/doi.org\/10.1001\/jama.300.4.413","journal-title":"JAMA"},{"key":"453_CR5","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1001\/jama.2011.1829","volume":"306","author":"JS Boomer","year":"2011","unstructured":"Boomer JS, To K, Chang KC et al (2011) Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA 306:2594\u20132605. https:\/\/doi.org\/10.1001\/jama.2011.1829","journal-title":"JAMA"},{"key":"453_CR6","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1128\/IAI.01213-09","volume":"78","author":"JT Muenzer","year":"2010","unstructured":"Muenzer JT, Davis CG, Chang K et al (2010) Characterization and modulation of the immunosuppressive phase of sepsis. Infect Immun 78:1582\u20131592. https:\/\/doi.org\/10.1128\/IAI.01213-09","journal-title":"Infect Immun"},{"key":"453_CR7","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/S1473-3099(12)70136-6","volume":"12","author":"J Cohen","year":"2012","unstructured":"Cohen J, Opal S, Calandra T (2012) Sepsis studies need new direction. Lancet Infect Dis 12:503\u2013505. https:\/\/doi.org\/10.1016\/S1473-3099(12)70136-6","journal-title":"Lancet Infect Dis"},{"key":"453_CR8","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1001\/jama.2016.2691","volume":"315","author":"LA van Vught","year":"2016","unstructured":"van Vught LA, Klein Klouwenberg PMC, Spitoni C et al (2016) Incidence, risk factors, and attributable mortality of secondary infections in the intensive care unit after admission for sepsis. JAMA 315:1469\u20131479. https:\/\/doi.org\/10.1001\/jama.2016.2691","journal-title":"JAMA"},{"key":"453_CR9","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1146\/annurev-physiol-061121-040214","volume":"84","author":"LK Torres","year":"2022","unstructured":"Torres LK, Pickkers P, van der Poll T (2022) Sepsis-induced immunosuppression. Annu Rev Physiol 84:157\u2013181. https:\/\/doi.org\/10.1146\/annurev-physiol-061121-040214","journal-title":"Annu Rev Physiol"},{"key":"453_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.cd005341.pub3","author":"LJ Estcourt","year":"2015","unstructured":"Estcourt LJ, Stanworth SJ, Doree C et al (2015) Granulocyte transfusions for preventing infections in people with neutropenia or neutrophil dysfunction. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.cd005341.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"453_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003956.pub2","author":"M Pammi","year":"2011","unstructured":"Pammi M, Brocklehurst P (2011) Granulocyte transfusions for neonates with confirmed or suspected sepsis and neutropenia. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD003956.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"453_CR12","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1002\/cncr.20710","volume":"101","author":"A Safdar","year":"2004","unstructured":"Safdar A, Hanna HA, Boktour M et al (2004) Impact of high-dose granulocyte transfusions in patients with cancer with candidemia. Cancer 101:2859\u20132865. https:\/\/doi.org\/10.1002\/cncr.20710","journal-title":"Cancer"},{"key":"453_CR13","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1186\/s13054-018-2181-z","volume":"22","author":"G Ankawi","year":"2018","unstructured":"Ankawi G, Neri M, Zhang J et al (2018) Extracorporeal techniques for the treatment of critically ill patients with sepsis beyond conventional blood purification therapy: the promises and the pitfalls. Crit Care 22:262. https:\/\/doi.org\/10.1186\/s13054-018-2181-z","journal-title":"Crit Care"},{"key":"453_CR14","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/cc9411","volume":"15","author":"T Rimmel\u00e9","year":"2011","unstructured":"Rimmel\u00e9 T, Kellum JA (2011) Clinical review: Blood purification for sepsis. Crit Care 15:205. https:\/\/doi.org\/10.1186\/cc9411","journal-title":"Crit Care"},{"key":"453_CR15","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/ki.2011.375","volume":"81","author":"AM Shukla","year":"2012","unstructured":"Shukla AM (2012) Extracorporeal therapy in sepsis: are we there yet? Kidney Int 81:336\u2013338. https:\/\/doi.org\/10.1038\/ki.2011.375","journal-title":"Kidney Int"},{"key":"453_CR16","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1097\/01.shk.0000143410.63698.57","volume":"22","author":"V Caille","year":"2004","unstructured":"Caille V, Chiche J-D, Nciri N et al (2004) Histocompatibility leukocyte antigen-D related expression is specifically altered and predicts mortality in septic shock but not in other causes of shock. Shock 22:521\u2013526. https:\/\/doi.org\/10.1097\/01.shk.0000143410.63698.57","journal-title":"Shock"},{"key":"453_CR17","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1172\/JCI82224","volume":"126","author":"MJ Delano","year":"2016","unstructured":"Delano MJ, Ward PA (2016) Sepsis-induced immune dysfunction: can immune therapies reduce mortality? J Clin Invest 126:23\u201331. https:\/\/doi.org\/10.1172\/JCI82224","journal-title":"J Clin Invest"},{"key":"453_CR18","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1097\/00003246-200205000-00017","volume":"30","author":"BM Tavares-Murta","year":"2002","unstructured":"Tavares-Murta BM, Zaparoli M, Ferreira RB et al (2002) Failure of neutrophil chemotactic function in septic patients. Crit Care Med 30:1056\u20131061. https:\/\/doi.org\/10.1097\/00003246-200205000-00017","journal-title":"Crit Care Med"},{"key":"453_CR19","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1046\/j.1526-0968.2001.00378.x","volume":"5","author":"SR Mitzner","year":"2021","unstructured":"Mitzner SR, Freytag J, Sauer M et al (2021) Use of human preconditioned phagocytes for extracorporeal immune support: Introduction of a concept. Ther Apher Dial 5:423\u2013432","journal-title":"Ther Apher Dial"},{"key":"453_CR20","doi-asserted-by":"publisher","first-page":"R82","DOI":"10.1186\/cc10076","volume":"15","author":"J Altrichter","year":"2011","unstructured":"Altrichter J, Sauer M, Kaftan K et al (2011) Extracorporeal cell therapy of septic shock patients with donor granulocytes: a pilot study. Crit Care 15:R82. https:\/\/doi.org\/10.1186\/cc10076","journal-title":"Crit Care"},{"key":"453_CR21","doi-asserted-by":"publisher","first-page":"7056492","DOI":"10.1155\/2016\/7056492","volume":"2016","author":"M Sauer","year":"2016","unstructured":"Sauer M, Altrichter J, Haubner C et al (2016) Bioartificial therapy of sepsis: changes of norepinephrine-dosage in patients and influence on dynamic and cell based liver tests during extracorporeal treatments. Biomed Res Int 2016:7056492. https:\/\/doi.org\/10.1155\/2016\/7056492","journal-title":"Biomed Res Int"},{"key":"453_CR22","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1111\/j.1744-9987.2009.00764.x","volume":"13","author":"M Sauer","year":"2009","unstructured":"Sauer M, Altrichter J, Kreutzer H-J et al (2009) Safety evaluation for a cell-based immune support system in an ex vivo rat model of gram-negative sepsis. Ther Apher Dial 13:444\u2013450. https:\/\/doi.org\/10.1111\/j.1744-9987.2009.00764.x","journal-title":"Ther Apher Dial"},{"key":"453_CR23","doi-asserted-by":"publisher","DOI":"10.1111\/trf.16732","author":"G Klinkmann","year":"2021","unstructured":"Klinkmann G, Doss F, Goudeva L et al (2021) Prolonged storage of purified granulocyte concentrates: introduction of a new purification method. Transfusion. https:\/\/doi.org\/10.1111\/trf.16732","journal-title":"Transfusion"},{"key":"453_CR24","unstructured":"(2021) Querschnitts-Leitlinien (B\u00c4K) zur Therapie mit Blutkomponenten und Plasmaderivaten \u2013 Gesamtnovelle 2020. https:\/\/www.bundesaerztekammer.de\/aerzte\/medizin-ethik\/wissenschaftlicher-beirat\/veroeffentlichungen\/haemotherapietransfusionsmedizin\/querschnitt-leitlinie\/. Accessed 26 Oct 2021"},{"key":"453_CR25","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3109\/00365515909060410","volume":"11","author":"M Harboe","year":"1959","unstructured":"Harboe M (1959) A method for determination of hemoglobin in plasma by near-ultraviolet spectrophotometry. Scand J Clin Lab Invest 11:66\u201370. https:\/\/doi.org\/10.3109\/00365515909060410","journal-title":"Scand J Clin Lab Invest"},{"key":"453_CR26","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1126\/science.8140420","volume":"264","author":"K Rajarathnam","year":"1994","unstructured":"Rajarathnam K, Sykes BD, Kay CM et al (1994) Neutrophil activation by monomeric interleukin-8. Science 264:90\u201392. https:\/\/doi.org\/10.1126\/science.8140420","journal-title":"Science"},{"key":"453_CR27","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1097\/MOH.0000000000000389","volume":"25","author":"V Bianconi","year":"2018","unstructured":"Bianconi V, Sahebkar A, Atkin SL, Pirro M (2018) The regulation and importance of monocyte chemoattractant protein-1. Curr Opin Hematol 25:44\u201351. https:\/\/doi.org\/10.1097\/MOH.0000000000000389","journal-title":"Curr Opin Hematol"},{"key":"453_CR28","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1007\/s00134-002-1410-7","volume":"28","author":"R Busund","year":"2002","unstructured":"Busund R, Koukline V, Utrobin U, Nedashkovsky E (2002) Plasmapheresis in severe sepsis and septic shock: a prospective, randomised, controlled trial. Intensive Care Med 28:1434\u20131439. https:\/\/doi.org\/10.1007\/s00134-002-1410-7","journal-title":"Intensive Care Med"},{"key":"453_CR29","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1007\/s00134-020-06339-1","volume":"47","author":"S David","year":"2021","unstructured":"David S, Bode C, Putensen C et al (2021) Adjuvant therapeutic plasma exchange in septic shock. Intensive Care Med 47:352\u2013354. https:\/\/doi.org\/10.1007\/s00134-020-06339-1","journal-title":"Intensive Care Med"},{"key":"453_CR30","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1007\/s00134-021-06501-3","volume":"47","author":"E Garbero","year":"2021","unstructured":"Garbero E, Livigni S, Ferrari F et al (2021) High dose coupled plasma filtration and adsorption in septic shock patients. Results of the COMPACT-2: a multicentre, adaptive, randomised clinical trial. Intensive Care Med 47:1303\u20131311. https:\/\/doi.org\/10.1007\/s00134-021-06501-3","journal-title":"Intensive Care Med"},{"key":"453_CR31","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1007\/s00134-021-06512-0","volume":"47","author":"PD Wendel Garcia","year":"2021","unstructured":"Wendel Garcia PD, Hilty MP, Held U et al (2021) Cytokine adsorption in severe, refractory septic shock. Intensive Care Med 47:1334\u20131336. https:\/\/doi.org\/10.1007\/s00134-021-06512-0","journal-title":"Intensive Care Med"},{"key":"453_CR32","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/S2213-2600(21)00177-6","volume":"9","author":"A Supady","year":"2021","unstructured":"Supady A, Weber E, Rieder M et al (2021) Cytokine adsorption in patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation (CYCOV): a single centre, open-label, randomised, controlled trial. Lancet Respir Med 9:755\u2013762. https:\/\/doi.org\/10.1016\/S2213-2600(21)00177-6","journal-title":"Lancet Respir Med"},{"key":"453_CR33","doi-asserted-by":"publisher","first-page":"803","DOI":"10.3390\/ijms23020803","volume":"23","author":"A Lazzaro","year":"2022","unstructured":"Lazzaro A, De Girolamo G, Filippi V et al (2022) The Interplay between Host Defense, Infection, and Clinical Status in Septic Patients: A Narrative Review. Int J Mol Sci 23:803. https:\/\/doi.org\/10.3390\/ijms23020803","journal-title":"Int J Mol Sci"},{"key":"453_CR34","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1007\/s00134-021-06560-6","volume":"48","author":"K Stahl","year":"2022","unstructured":"Stahl K, Wendel-Garcia PD, Bode C, David S (2022) Unraveling the secret of re-balancing homeostasis in sepsis: a critical view on extracorporeal blood purification modalities. Intensive Care Med 48:130\u2013132. https:\/\/doi.org\/10.1007\/s00134-021-06560-6","journal-title":"Intensive Care Med"}],"container-title":["Intensive Care Medicine Experimental"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40635-022-00453-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40635-022-00453-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40635-022-00453-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T13:16:59Z","timestamp":1655385419000},"score":1,"resource":{"primary":{"URL":"https:\/\/icm-experimental.springeropen.com\/articles\/10.1186\/s40635-022-00453-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,16]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["453"],"URL":"https:\/\/doi.org\/10.1186\/s40635-022-00453-8","relation":{},"ISSN":["2197-425X"],"issn-type":[{"type":"electronic","value":"2197-425X"}],"subject":[],"published":{"date-parts":[[2022,6,16]]},"assertion":[{"value":"19 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The ethical basis of preparation and utilization of granulocyte concentrates in the Institute of Transfusion Medicine and Transplant Engineering, Hannover Medical School, Germany including scientific purposes is of general validity and in accordance with informed consent of the donors that covers the procedure of this experimental investigation and for scientific publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All coauthors provided consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"FD, SD, TW, BH, SM, JA are employees or shareholders of ARTCLINE GmbH.All other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"26"}}